
    
      The primary objective of this study is to evaluate the efficacy of eltrombopag for poor graft
      function on overall hematologic response (partial and complete), as determined by platelet,
      hemoglobin and neutrophil counts by 16 weeks after the initiation of eltrombopag.
    
  